Clinical  ||| S:0 E:9 ||| JJ
roundtable  ||| S:9 E:20 ||| JJ
monograph ||| S:20 E:29 ||| NN
:  ||| S:29 E:31 ||| :
Recent  ||| S:31 E:38 ||| JJ
advances  ||| S:38 E:47 ||| NNS
in  ||| S:47 E:50 ||| IN
taxanes  ||| S:50 E:58 ||| NN
for  ||| S:58 E:62 ||| IN
the  ||| S:62 E:66 ||| DT
first-line  ||| S:66 E:77 ||| JJ
treatment  ||| S:77 E:87 ||| NN
of  ||| S:87 E:90 ||| IN
advanced  ||| S:90 E:99 ||| JJ
non-small  ||| S:99 E:109 ||| JJ
cell  ||| S:109 E:114 ||| NN
lung  ||| S:114 E:119 ||| NN
cancer  ||| S:119 E:126 ||| NN
Treatments  ||| S:126 E:137 ||| NNS
for  ||| S:137 E:141 ||| IN
non-small  ||| S:141 E:151 ||| JJ
cell  ||| S:151 E:156 ||| NN
lung  ||| S:156 E:161 ||| NN
cancer  ||| S:161 E:168 ||| NN
( ||| S:168 E:169 ||| -LRB-
NSCLC ||| S:169 E:174 ||| NNP
)  ||| S:174 E:176 ||| -RRB-
are  ||| S:176 E:180 ||| VBP
based  ||| S:180 E:186 ||| VBN
on  ||| S:186 E:189 ||| IN
the  ||| S:189 E:193 ||| DT
broad  ||| S:193 E:199 ||| JJ
categories  ||| S:199 E:210 ||| NNS
of  ||| S:210 E:213 ||| IN
squamous  ||| S:213 E:222 ||| NN
or  ||| S:222 E:225 ||| CC
non-squamous  ||| S:225 E:238 ||| JJ
histology ||| S:238 E:247 ||| NN
.  ||| S:247 E:249 ||| .
Frontline  ||| S:249 E:259 ||| JJ
treatment  ||| S:259 E:269 ||| NN
options  ||| S:269 E:277 ||| NNS
include  ||| S:277 E:285 ||| VBP
pemetrexed  ||| S:285 E:296 ||| VBN
and  ||| S:296 E:300 ||| CC
cisplatin ||| S:300 E:309 ||| NN
,  ||| S:309 E:311 ||| ,
pemetrexed  ||| S:311 E:322 ||| NN
and  ||| S:322 E:326 ||| CC
a  ||| S:326 E:328 ||| DT
taxane ||| S:328 E:334 ||| NN
,  ||| S:334 E:336 ||| ,
gemcitabine  ||| S:336 E:348 ||| VBG
with  ||| S:348 E:353 ||| IN
cisplatin ||| S:353 E:362 ||| NN
,  ||| S:362 E:364 ||| ,
and  ||| S:364 E:368 ||| CC
the  ||| S:368 E:372 ||| DT
addition  ||| S:372 E:381 ||| NN
of  ||| S:381 E:384 ||| IN
bevacizumab  ||| S:384 E:396 ||| VBG
to  ||| S:396 E:399 ||| TO
a  ||| S:399 E:401 ||| DT
taxane  ||| S:401 E:408 ||| NN
and  ||| S:408 E:412 ||| CC
carboplatin ||| S:412 E:423 ||| NN
.  ||| S:423 E:425 ||| .
Pemetrexed  ||| S:425 E:436 ||| NNP
is  ||| S:436 E:439 ||| VBZ
used  ||| S:439 E:444 ||| VBN
for  ||| S:444 E:448 ||| IN
maintenance  ||| S:448 E:460 ||| NN
therapy  ||| S:460 E:468 ||| NN
for  ||| S:468 E:472 ||| IN
non-squamous  ||| S:472 E:485 ||| NNP
NSCLC ||| S:485 E:490 ||| NNP
,  ||| S:490 E:492 ||| ,
whereas  ||| S:492 E:500 ||| IN
patients  ||| S:500 E:509 ||| NNS
with  ||| S:509 E:514 ||| IN
squamous  ||| S:514 E:523 ||| JJ
NSCLC  ||| S:523 E:529 ||| NNS
lack  ||| S:529 E:534 ||| VBP
easy  ||| S:534 E:539 ||| JJ
options  ||| S:539 E:547 ||| NNS
for  ||| S:547 E:551 ||| IN
maintenance  ||| S:551 E:563 ||| NN
therapy.  ||| S:563 E:572 ||| NNP
nab-Paclitaxel  ||| S:572 E:587 ||| NNP
overcomes  ||| S:587 E:597 ||| VBZ
the  ||| S:597 E:601 ||| DT
solubility  ||| S:601 E:612 ||| NN
and  ||| S:612 E:616 ||| CC
toxicity  ||| S:616 E:625 ||| JJ
issues  ||| S:625 E:632 ||| NNS
of  ||| S:632 E:635 ||| IN
solvent-based  ||| S:635 E:649 ||| JJ
paclitaxel ||| S:649 E:659 ||| NN
,  ||| S:659 E:661 ||| ,
and  ||| S:661 E:665 ||| CC
the  ||| S:665 E:669 ||| DT
albumin  ||| S:669 E:677 ||| NN
in  ||| S:677 E:680 ||| IN
nab-paclitaxel  ||| S:680 E:695 ||| NNP
improves  ||| S:695 E:704 ||| VBZ
the  ||| S:704 E:708 ||| DT
concentration  ||| S:708 E:722 ||| NN
of  ||| S:722 E:725 ||| IN
the  ||| S:725 E:729 ||| DT
drug  ||| S:729 E:734 ||| NN
in  ||| S:734 E:737 ||| IN
the  ||| S:737 E:741 ||| DT
tumor ||| S:741 E:746 ||| NN
.  ||| S:746 E:748 ||| .
A  ||| S:748 E:750 ||| DT
recent  ||| S:750 E:757 ||| JJ
phase  ||| S:757 E:763 ||| NN
III  ||| S:763 E:767 ||| NNP
trial  ||| S:767 E:773 ||| NN
in  ||| S:773 E:776 ||| IN
NSCLC  ||| S:776 E:782 ||| NNP
compared  ||| S:782 E:791 ||| VBD
nab-paclitaxel  ||| S:791 E:806 ||| JJ
with  ||| S:806 E:811 ||| IN
carboplatin  ||| S:811 E:823 ||| FW
versus  ||| S:823 E:830 ||| FW
solvent-based  ||| S:830 E:844 ||| FW
paclitaxel  ||| S:844 E:855 ||| FW
with  ||| S:855 E:860 ||| IN
carboplatin ||| S:860 E:871 ||| NN
,  ||| S:871 E:873 ||| ,
and  ||| S:873 E:877 ||| CC
found  ||| S:877 E:883 ||| VBD
improved  ||| S:883 E:892 ||| VBN
overall  ||| S:892 E:900 ||| JJ
response  ||| S:900 E:909 ||| NN
rates  ||| S:909 E:915 ||| NNS
( ||| S:915 E:916 ||| -LRB-
ORRs ||| S:916 E:920 ||| NNP
)  ||| S:920 E:922 ||| -RRB-
in  ||| S:922 E:925 ||| IN
the  ||| S:925 E:929 ||| DT
nab-paclitaxel  ||| S:929 E:944 ||| JJ
arm  ||| S:944 E:948 ||| NN
( ||| S:948 E:949 ||| -LRB-
33 ||| S:949 E:951 ||| CD
%  ||| S:951 E:953 ||| NN
vs  ||| S:953 E:956 ||| VBD
25 ||| S:956 E:958 ||| CD
% ||| S:958 E:959 ||| NN
;  ||| S:959 E:961 ||| :
P=.005 ||| S:961 E:967 ||| CD
) ||| S:967 E:968 ||| -RRB-
.  ||| S:968 E:970 ||| .
In  ||| S:970 E:973 ||| IN
a  ||| S:973 E:975 ||| DT
subset  ||| S:975 E:982 ||| JJ
analysis ||| S:982 E:990 ||| NN
,  ||| S:990 E:992 ||| ,
NSCLC  ||| S:992 E:998 ||| NNP
patients  ||| S:998 E:1007 ||| NNS
with  ||| S:1007 E:1012 ||| IN
squamous  ||| S:1012 E:1021 ||| JJ
histology  ||| S:1021 E:1031 ||| NN
had  ||| S:1031 E:1035 ||| VBD
a  ||| S:1035 E:1037 ||| DT
higher  ||| S:1037 E:1044 ||| JJR
ORR  ||| S:1044 E:1048 ||| NNP
( ||| S:1048 E:1049 ||| -LRB-
41 ||| S:1049 E:1051 ||| CD
% ||| S:1051 E:1052 ||| NN
)  ||| S:1052 E:1054 ||| -RRB-
with  ||| S:1054 E:1059 ||| IN
nab-paclitaxel  ||| S:1059 E:1074 ||| JJ
than  ||| S:1074 E:1079 ||| IN
with  ||| S:1079 E:1084 ||| IN
solvent-based  ||| S:1084 E:1098 ||| JJ
paclitaxel  ||| S:1098 E:1109 ||| NNS
( ||| S:1109 E:1110 ||| -LRB-
24 ||| S:1110 E:1112 ||| CD
% ||| S:1112 E:1113 ||| NN
;  ||| S:1113 E:1115 ||| :
P  ||| S:1115 E:1116 ||| NNP
< ||| S:1116 E:1117 ||| SYM
.001 ||| S:1117 E:1121 ||| NNP
) ||| S:1121 E:1122 ||| -RRB-
.  ||| S:1122 E:1124 ||| .
Another  ||| S:1124 E:1132 ||| DT
subset  ||| S:1132 E:1139 ||| JJ
analysis  ||| S:1139 E:1148 ||| NN
found  ||| S:1148 E:1154 ||| VBD
that  ||| S:1154 E:1159 ||| IN
patients  ||| S:1159 E:1168 ||| NNS
ages  ||| S:1168 E:1173 ||| VBD
70  ||| S:1173 E:1176 ||| CD
years  ||| S:1176 E:1182 ||| NNS
and  ||| S:1182 E:1186 ||| CC
older  ||| S:1186 E:1192 ||| JJR
had  ||| S:1192 E:1196 ||| VBD
improved  ||| S:1196 E:1205 ||| VBN
overall  ||| S:1205 E:1213 ||| JJ
survival  ||| S:1213 E:1222 ||| NN
( ||| S:1222 E:1223 ||| -LRB-
median  ||| S:1223 E:1230 ||| JJ
19.9  ||| S:1230 E:1235 ||| CD
months ||| S:1235 E:1241 ||| NNS
)  ||| S:1241 E:1243 ||| -RRB-
with  ||| S:1243 E:1248 ||| IN
nab-paclitaxel  ||| S:1248 E:1263 ||| JJ
compared  ||| S:1263 E:1272 ||| VBN
with  ||| S:1272 E:1277 ||| IN
solvent-based  ||| S:1277 E:1291 ||| JJ
paclitaxel  ||| S:1291 E:1302 ||| NNS
( ||| S:1302 E:1303 ||| -LRB-
median  ||| S:1303 E:1310 ||| JJ
10.4  ||| S:1310 E:1315 ||| CD
months ||| S:1315 E:1321 ||| NNS
;  ||| S:1321 E:1323 ||| :
P=.009 ||| S:1323 E:1329 ||| CD
) ||| S:1329 E:1330 ||| -RRB-
.  ||| S:1330 E:1332 ||| .
Patients  ||| S:1332 E:1341 ||| NNS
in  ||| S:1341 E:1344 ||| IN
the  ||| S:1344 E:1348 ||| DT
nab-paclitaxel  ||| S:1348 E:1363 ||| JJ
arm  ||| S:1363 E:1367 ||| NN
had  ||| S:1367 E:1371 ||| VBD
less  ||| S:1371 E:1376 ||| JJR
neuropathy ||| S:1376 E:1386 ||| NN
,  ||| S:1386 E:1388 ||| ,
less  ||| S:1388 E:1393 ||| JJR
hearing  ||| S:1393 E:1401 ||| NN
loss ||| S:1401 E:1405 ||| NN
,  ||| S:1405 E:1407 ||| ,
and  ||| S:1407 E:1411 ||| CC
fewer  ||| S:1411 E:1417 ||| JJR
interruptions  ||| S:1417 E:1431 ||| NNS
in  ||| S:1431 E:1434 ||| IN
daily  ||| S:1434 E:1440 ||| JJ
living  ||| S:1440 E:1447 ||| NN
than  ||| S:1447 E:1452 ||| IN
patients  ||| S:1452 E:1461 ||| NNS
in  ||| S:1461 E:1464 ||| IN
the  ||| S:1464 E:1468 ||| DT
solvent-based  ||| S:1468 E:1482 ||| JJ
paclitaxel  ||| S:1482 E:1493 ||| JJ
arm ||| S:1493 E:1496 ||| NN
.  ||| S:1496 E:1498 ||| .
